Using state-of-the-art mass spectrometry instrumentation, I am now analyzing 40 human tumor samples via an advanced protein-based molecular profiling approach. The rationale for the proposed work is that, once the optimal method parameters are established using advanced mass spectrometry and relevant oncoproteomic technologies to facilitate method development, to investigate a solid tumor of interest, homogeneous histological tumor/tissue cells (i.e., tumor proper, stroma, etc) can be effectively studied for biomarkers, drug targets, and pathways, with the goal of improving our basic understanding of a given disease-state.
|Ye, Xiaoying; Luke, Brian T; Johann Jr, Donald J et al. (2010) Optimized method for computing (18)O/(16)O ratios of differentially stable-isotope labeled peptides in the context of postdigestion (18)O exchange/labeling. Anal Chem 82:5878-86|
|Johann Jr, Donald J; Wei, Bih-Rong; Prieto, DaRue A et al. (2010) Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem 82:1584-8|
|Johann, Donald J; Rodriguez-Canales, Jaime; Mukherjee, Sumana et al. (2009) Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 8:2310-8|
|Mbeunkui, Flaubert; Johann Jr, Donald J (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63:571-82|